Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting

Dinleyici, Ener Çağrı; Dalgıç, Nazan; Güven, Şirin; Metin, Özge; Yasa, Olcay; Kurugöl, Zafer; Türel, Özden; Tanır, Gönül; Yazar, Ahmet Sami; Arıca, Vefik; Sancar, Mesut; Karbuz, Adem; Eren, Makbule; Özen, Metehan; Kara, Ateş; Vandenplas, Yvan

doi:10.1016/j.jped.2014.10.009

Cited by 52 publications

(33 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The positive impact on the length of diarrhea was consistent with the findings of the present study [30]. In another study, Golam H. Rabbani et al studied the impact of green banana on clinical severity of childhood shigellosis.…”

Section: Discussionsupporting

confidence: 92%

Efficacy of Synbiotics for Treatment of Bacillary Dysentery in Children: A Double-Blind, Randomized, Placebo-Controlled Study

Kahbazi

Ebrahimi

Zarinfar

et al. 2016

Advances in Medicine

View full text Add to dashboard Cite

Bacillary dysentery is a major cause of children's admission to hospitals. To assess the probiotic and prebiotic (synbiotics) effects in children with dysentery in a randomized clinical trial, 200 children with dysentery were studied in 2 groups: the synbiotic group received 1 tablet/day of synbiotic for 3–5 days and the placebo group received placebo tablets (identical tablet form like probiotics). The standard treatment was administered for all patients. Duration of hospitalization, dysentery, fever, and the weight loss were assessed in each group. It was concluded that there was no significant difference in both groups in the baseline characteristics. The mean duration of dysentery reduced (P < 0.05). The mean duration of fever has been significantly reduced in the synbiotic group (1.64 ± 0.87 days) in comparison to the placebo group (2.13 ± 0.94 days) (P < 0.001). Average amount of weight loss was significantly lower in the synbiotic group in comparison to that in the placebo group (129.5 ± 23.388 grams and 278 ± 28.385 grams, resp.; P < 0.001). There was no significant difference in the mean duration of hospitalization in both groups (P > 0.05). The use of synbiotics as an adjuvant therapy to the standard treatment of dysentery significantly reduces the duration of dysentery, fever, and rate of weight losses. The trial is registered with IRCT201109267647N1.

show abstract

Section: Discussionsupporting

confidence: 92%

Efficacy of Synbiotics for Treatment of Bacillary Dysentery in Children: A Double-Blind, Randomized, Placebo-Controlled Study

Kahbazi

Ebrahimi

Zarinfar

et al. 2016

Advances in Medicine

View full text Add to dashboard Cite

show abstract

“…All included trials were randomised and were either double‐blind or single‐blind studies. Three RCTs ( n = 256) reported data on the effect of L. reuteri DSM 17938 in the treatment of diarrhoea . These studies included children aged 3–60 months who were hospitalised or treated as out‐patients .…”

Section: Resultsmentioning

confidence: 99%

“…Three RCTs ( n = 256) reported data on the effect of L. reuteri DSM 17938 in the treatment of diarrhoea . These studies included children aged 3–60 months who were hospitalised or treated as out‐patients . L. reuteri DSM 17938 was administered at a dose ranging from 1 × 10 8 colony‐forming units (CFU) to 4 × 10 8 CFU daily for 5–7 days.…”

Section: Resultsmentioning

confidence: 99%

Systematic review with meta‐analysis: Lactobacillus reuteri DSM 17938 for diarrhoeal diseases in children

Urbańska

Gieruszczak‐Białek

Szajewska

2016

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Probiotics are defined as ‘live microorganisms that when consumed in adequate amounts confer a health benefit on the host’ by improving the composition of gut microflora [3]. Previous studies demonstrated that probiotics have beneficial effects on cancer [4, 5], diarrhea [6, 7], and irritable bowel disease [8, 9]. In addition, in our previous paper [10], we showed that probiotics have a potential anti-inflammatory effect by reducing secretion of the pro-inflammatory cytokine, TNF-α.…”

Section: Introductionmentioning

confidence: 99%

Effects of Bifidobacterium animalis subsp. lactis BB-12® on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial

Lee

Roberts

et al. 2017

Nutr J

View full text Add to dashboard Cite

BackgroundSome probiotics have hypocholesterolemic effects in animal studies, which are mediated, in part, by increases in fecal short chain fatty acids (SCFAs). Clinical trials of probiotics on lipids/lipoproteins are inconsistent.ObjectiveWe examined the effects of Bifidobacterium animalis subsp. lactis BB-12® (BB-12®) (3.16 × 109 CFUs/day) on lipids and lipoproteins and fecal excretion of SCFAs in healthy adults.MethodsIn a randomized, partially blinded, 4-period, crossover study, 30 adults (11 men, 19 women) aged 18–40 years were randomly assigned to: 1) yogurt smoothie with no BB-12® (YS), 2) yogurt smoothie with BB-12® added pre-fermentation (PRE), 3) yogurt smoothie with BB-12® added post-fermentation (POST), 4) BB-12® containing capsule (CAP). We measured serum lipids/lipoproteins, glucose, insulin, C-reactive protein (CRP), and fecal SCFAs at baseline and after each treatment period.ResultsTotal cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and triglycerides (TGs) did not differ after the PRE, POST, and CAP periods versus the YS or between treatments. Compared to baseline, fecal acetate was significantly increased after the YS (Δ = 211.89 ± 75.87 μg/g, P = 0.007) and PRE (Δ = 204.98 ± 75.70 μg/g, P = 0.009) periods. The percent increase in fecal acetate was significantly greater after the YS versus the POST period (52.2 ± 13.2% vs. 24.5 ± 13.2%, P = 0.023). Fecal total SCFAs, propionate and butyrate did not differ between treatment periods. Fecal total SCFAs were negatively associated with TC (r = -0.22, P = 0.01), LDL-C (r = -0.24, P = 0.004), age (r = -0.33, P < 0.001), and waist circumference (r = -0.25, P = 0.003).ConclusionsBB-12® supplementation did not improve lipids, lipoproteins and total and individual fecal SCFAs. Fecal SCFAs were negatively associated with TC, LDL-C, age, and waist circumference.Trial registrationThis trial was registered at clinicaltrials.gov as NCT01399996.

show abstract

Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting

Abstract: L. reuteri DSM 17938 is effective, safe, and well-tolerated in outpatient children with acute infectious diarrhea.

Cited by 52 publications

References 12 publications

Efficacy of Synbiotics for Treatment of Bacillary Dysentery in Children: A Double-Blind, Randomized, Placebo-Controlled Study

Efficacy of Synbiotics for Treatment of Bacillary Dysentery in Children: A Double-Blind, Randomized, Placebo-Controlled Study

Systematic review with meta‐analysis: Lactobacillus reuteri DSM 17938 for diarrhoeal diseases in children

Effects of Bifidobacterium animalis subsp. lactis BB-12® on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial

Contact Info

Product

Resources

About